Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 4/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL4204680 | 0.86 | CHRM1 (0.52) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4205210 | 0.83 | CHRM1 (0.52) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Iodide SCHEMBL4210154 | 0.79 | CHRM1 (0.48) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4199213 | 0.75 | CHRM2 (0.52) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL14507228 | 0.74 | CHRM1 (0.45) | CHRM1 | |
| Hydrochloric Acid SCHEMBL9469130 | 0.74 | CHRM2 (0.44) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4206274 | 0.73 | CHRM2 (0.53) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4198068 | 0.73 | CHRM2 (0.70) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Methane SCHEMBL4192825 | 0.73 | CHRM2 (0.50) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL4209242 | 0.72 | CHRM2 (0.52) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005390-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S | 2009-01-01 | — | — | US | claimed |
| US-20050245567-A1 | Novel quinuclidine derivatives and their use | NEUROSEARCH A/S (DK) | 2005-11-03 | — | — | US | claimed |
| EP-1532144-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2005-05-25 | — | — | EP | claimed |
| WO-2004016608-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2004-02-26 | — | — | WO | claimed |
| US-20090005390-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S | 2009-01-01 | — | — | US | disclosed |
| EP-1905771-A2 | Quinuclidine derivatives and their use | NeuroSearch A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| US-20050245567-A1 | Novel quinuclidine derivatives and their use | NEUROSEARCH A/S (DK) | 2005-11-03 | — | — | US | disclosed |
| EP-1532144-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004016608-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005390-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | ACHE, CHRNA5, CHRNA3 | CHRM1 28/4885CHRM2 20/4885CHRM4 19/4885 |
| US-20050245567-A1 | Novel quinuclidine derivatives and their use | ACHE, CHRNA5, CHRNA3 | CHRM1 28/4885CHRM2 20/4885CHRM4 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.